Inside This Issue  by unknown
MARCH 15, 2011
VOLUME 57, NO. 11
JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY
Inside This Issue
STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1251Significance of Clopidogrel–Drug InteractionsEric R. Bates, Wei C. Lau, Dominick J. Angiolillo
Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation.
Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic
studies to competitively inhibit CYP activation of clopidogrel. Bates and colleagues review the
clinical implications of these interactions and conclude that, to date, there is no consistent
evidence that clopidogrel–drug interactions adversely impact cardiovascular events. Clinicians
concerned about clopidogrel–drug interactions have the option of prescribing either an
alternative platelet P2Y12 receptor inhibitor without known drug interactions or statin and
gastro-protective agents that do not interfere with clopidogrel metabolism.CLINICAL RESEARCH ANTITHROMBOTIC THERAPY1264Cilostazol May Inhibit Intimal Hyperplasia and RestenosisSeung-Whan Lee, Seong-Wook Park, Young-Hak Kim, Sung-Cheol Yun, Duk-Woo Park, Cheol Whan Lee,
Soo-Jin Kang, Seung-Jung Park, Jae-Hwan Lee, Si Wan Choi, In-Whan Seong, Nae-Hee Lee,
Yoon Haeng Cho, Won-Yong Shin, Seung-Jin Lee, Se-Whan Lee, Min-Su Hyon, Duk-Won Bang,
Young-Jin Choi, Hyun-Sook Kim, Bong-Ki Lee, Keun Lee, Hoon-Ki Park, Chang-Bum Park, Sang-Gon Lee,
Min-Kyu Kim, Kyoung-Ha Park, Woo-Jung Park, for the DECLARE-LONG II Study Investigators
Lee and colleagues hypothesized that cilostazol would reduce intimal hyperplasia in
patients who receive long zotarolimus-eluting stents (stent length 30 mm). A total
of 500 patients were randomly assigned to triple (aspirin, clopidogrel, and cilostazol)
or dual (aspirin and clopidogrel) antiplatelet therapy. The in-stent and in-segment
late loss were significantly lower in the triple therapy group, and 12-month ischemic-
driven target lesion revascularization was reduced by almost 50%. Cilostazol appears to be
useful in preventing intimal hyperplasia and reducing the risk of angiographic restenosis.(continued on page A-28)
MARCH 15, 2011 (continued) A-28CARDIAC IMAGING1271Relationship Between Inflammatory Markers and CFRViola Vaccarino, Durreshahwar Khan, John Votaw, Tracy Faber, Emir Veledar, Dean P. Jones, Jack Goldberg,
Paolo Raggi, Arshed A. Quyyumi, J. Douglas Bremner
Vaccarino and colleagues examined the relationship between inflammation and coronary
microvascular function in asymptomatic individuals using positron emission tomography
(PET) to determine coronary flow reserve (CFR). Nearly 300 asymptomatic male
monozygotic and dizygotic twins underwent PET scanning and had blood drawn for
measurement of biomarkers of inflammation. In within-pair analyses, all biomarkers, except
vascular cell adhesion molecule-1, were higher in the twin with lower CFR. These results
show that a decrease in coronary microvascular function is accompanied by a systemic
inflammatory response in the early phases of coronary artery disease.CARDIAC IMAGING
1280Computed Tomography Coronary Opacification
May Be an Indirect Measure of Coronary Blood FlowBenjamin J. W. Chow, Malek Kass, Owen Gagné, Li Chen, Yeung Yam, Alexander Dick, George A. Wells
Chow and colleagues performed a proof-of-concept study to determine whether differences in
corrected coronary opacification (CCO), essentially the density of contrast within the coronary
lumen, can identify arteries with abnormal resting coronary flow. Attenuation values of
coronary lumen were measured pre- and post-stenoses and were normalized to the aorta.
Abnormal coronary flow (Thrombolysis In Myocardial Infarction flow grade 3) was
identified with a sensitivity of 83% and a specificity of 91%. Changes in CCO may be useful
for assessing the physiologic significance of coronary stenoses.Editorial Comment: Frank J. Rybicki, p. 1289PRE-PARTICIPATION ATHLETIC SCREENING1291Questioning the Efficacy of Mandatory Electrocardiographic Screening for AthletesArie Steinvil, Tamar Chundadze, David Zeltser, Ori Rogowski, Amir Halkin, Yair Galily, Haim Perluk,
Sami Viskin
Steinvil and colleagues studied the effectiveness of a mandatory pre-participation screening
program of athletes. The yearly number of cardiac arrest events among competitive athletes
was determined before and after the National Sport Law was enacted in Israel in 1997. This
law mandates screening of all athletes with resting electrocardiogram (ECG) and exercise
testing. The average yearly incidences during the decade before the law and the decade after
were 2.54 and 2.66 events per 100,000 person-years, respectively. These results question the
efficacy of mandatory ECG screening of athletes.
Editorial Comment: Alfred A. Bove, p. 1297(continued on page A-32)
MARCH 15, 2011 (continued) A-32METABOLIC SYNDROME1299Mediterranean Diet Improves Several Components of the Metabolic SyndromeChristina-Maria Kastorini, Haralampos J. Milionis, Katherine Esposito, Dario Giugliano,
John A. Goudevenos, Demosthenes B. Panagiotakos
Kastorini and colleagues performed a meta-analysis of epidemiological studies and clinical
trials to determine the effect of a Mediterranean diet on the components of the metabolic
syndrome. Fifty original research studies with over half a million participants were included in
the analysis. Adherence to the Mediterranean diet was associated with reduced risk of
metabolic syndrome, smaller waist circumference, and lower levels of triglycerides, blood
pressure, and glucose. These results show that this dietary pattern may be useful for the
primary and secondary prevention of the metabolic syndrome and its individual components.EXPEDITED PUBLICATIONS EXPEDITED PUBLICATIONS1314Neoatherosclerosis May Underlie Late Thrombotic Events After DESGaku Nakazawa, Fumiyuki Otsuka, Masataka Nakano, Marc Vorpahl, Saami K. Yazdani, Elena Ladich,
Frank D. Kolodgie, Aloke V. Finn, Renu Virmani
Nakazawa and colleagues reviewed the histology and clinical features of almost 300 autopsy
specimens sent to the CVPath Stent Registry to compare the histological changes after
percutaneous coronary intervention with bare-metal stents (BMS) or drug-eluting stents
(DES). Neoatherosclerosis, defined as clusters of lipid-laden foamy macrophages within the
neointima, was found in 31% of DES-treated lesions compared with only 16% of BMS
lesions. Neoatherosclerosis also seemed to occur earlier after DES. The unstable features of
neoatherosclerosis may be a contributing factor to late thrombotic events.Editorial Comment: L. Maximilian Buja, p. 1323
